Asset Details
Do you wish to reserve the book?
Renal clearable nanochelators for iron overload therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Renal clearable nanochelators for iron overload therapy
Do you wish to request the book?
Renal clearable nanochelators for iron overload therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Renal clearable nanochelators for iron overload therapy
2019
Overview
Iron chelators have been widely used to remove excess toxic iron from patients with secondary iron overload. However, small molecule-based iron chelators can cause adverse side effects such as infection, gastrointestinal bleeding, kidney failure, and liver fibrosis. Here we report renal clearable nanochelators for iron overload disorders. First, after a singledose intravenous injection, the nanochelator shows favorable pharmacokinetic properties, such as kidney-specific biodistribution and rapid renal excretion (>80% injected dose in 4 h), compared to native deferoxamine (DFO). Second, subcutaneous (SC) administration of nanochelators improves pharmacodynamics, as evidenced by a 7-fold increase in efficiency of urinary iron excretion compared to intravenous injection. Third, daily SC injections of the nanochelator for 5 days to iron overload mice and rats decrease iron levels in serum and liver. Furthermore, the nanochelator significantly reduces kidney damage caused by iron overload without demonstrating DFO’s own nephrotoxicity. This renal clearable nanochelator provides enhanced efficacy and safety.
The build-up of iron in the body can have serious consequences; current treatment therapies suffer from adverse side effects and toxicity. Here, the authors developed renal clearable nanochelators with improved pharmacodynamics and demonstrated their efficacy and safety in iron overload animal models.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Anemia
/ Animals
/ Bleeding
/ Deferoxamine - pharmacokinetics
/ Deferoxamine - therapeutic use
/ Design
/ Fibrosis
/ Humanities and Social Sciences
/ Iron
/ Iron Chelating Agents - chemistry
/ Iron Chelating Agents - pharmacology
/ Iron Chelating Agents - therapeutic use
/ Iron Overload - drug therapy
/ Kidneys
/ Liver
/ Male
/ Mice
/ Nanoparticles - ultrastructure
/ NMR
/ Plasma
/ Science
